Theravance Biopharma Sees Unusually High Options Volume (NASDAQ:TBPH)

Theravance Biopharma, Inc. (NASDAQ:TBPH) saw some unusual options trading on Tuesday. Stock traders acquired 6,696 put options on the company. This is an increase of approximately 983% compared to the typical volume of 618 put options.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. HC Wainwright boosted their price target on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a report on Monday. BTIG Research lowered their price target on Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating for the company in a research report on Tuesday. Wall Street Zen lowered Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Oppenheimer started coverage on Theravance Biopharma in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.60.

Trending Headlines about Theravance Biopharma

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company retains a strong cash runway and announced deep cost cuts — Q4 cash ~$326.5M, roughly $400M expected at end‑Q1 2026; management expects ~60% cost reduction (~$70M) and $60–70M of annualized cash flow after restructuring. This improves near‑term survival and value for remaining assets. Read More.
• Positive Sentiment: HC Wainwright raised its price target to $27, signaling at least one analyst sees upside or acquisition/strategic outcomes that could unlock value. Read More.
• Neutral Sentiment: BTIG cut its price target from $40 to $21 but kept a “buy” rating — a mixed signal that trims optimism but still leaves upside from current levels per that firm. Read More.
• Neutral Sentiment: Board has accelerated a strategic review and is working with advisors (Lazard) to evaluate alternatives, including a possible sale — this creates near‑term uncertainty but could produce value for shareholders depending on outcome. Read More.
• Negative Sentiment: Core negative: The Phase 3 CYPRESS study of ampreloxetine missed its primary endpoint (OHSA composite), prompting the company to halt the program — this removes the company’s lead clinical value driver and was the catalyst for the sharp sell‑off. Read More.
• Negative Sentiment: B. Riley cut its price target sharply to $14 (from $28) and kept a neutral rating — another negative analyst move that reduces perceived near‑term upside. Read More.
• Negative Sentiment: Market positioning is bearish: unusually large put‑option activity was recorded (6,696 puts, ~983% above average), reflecting trader downside bets and adding selling pressure to the stock.

Institutional Investors Weigh In On Theravance Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quarry LP purchased a new position in Theravance Biopharma during the third quarter valued at $26,000. Caitong International Asset Management Co. Ltd lifted its position in Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,411 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Theravance Biopharma by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 515 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC grew its holdings in Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Price Performance

Shares of TBPH opened at $13.66 on Thursday. The company has a 50-day simple moving average of $19.16 and a two-hundred day simple moving average of $16.85. The firm has a market capitalization of $692.15 million, a PE ratio of 23.96 and a beta of 0.17. Theravance Biopharma has a one year low of $7.90 and a one year high of $21.03.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.